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Peroxisome Proliferation due to Di(2-
ethyihexyl) Phthalate (DEHP): Species
Differences and Possible Mechanisms*
by Clifford R. Elcombet and Angela M. Mitchellt
The exposure ofcultured rat hepatocytes to mono(2-ethylhexyl)phthalate (MEHP) for 72 hr resulted in
marked inductionofperoxisomal enzymeactivity(13-oxidation; cyanide-insensitive palmitoyl CoAoxidase)
and concomitant increases in the number of peroxisomes. Similar treatment of cultured guinea pig,
marmoset, or human hepatocytes revealed little or no effect of MEHP. In order to eliminate possible
confounding influences of biotransformation, the proximate peroxisome proliferator(s) derived from
MEHP have been identified. Using cultured hepatocytes these agents were found to be metabolite VI
[mono(2-ethyl-5-oxohexyl) phthalate] and metabolite IX [mono(2-ethyl-5-hydroxyhexyl) phthalate]. The
addition of these "active" metabolites to cultured guinea pig, marmoset, or human hepatocytes again
revealed littleeffectuponperoxisomesorrelatedenzymeactivities(peroxisomal1-oxidationormicrosomal
lauric acid hydroxylation). These studies demonstrate a marked species difference in the response of
hepatocytes to MEHP-elicited peroxisome proliferation. Preliminary studies have also suggested that
peroxisomeproliferationduetoMEHPmaybeduetoaninitialbiochemical lesionoffattyacidmetabolism.
Introduction
Perhaps one ofthe most striking toxicological effects
of di(2-ethylhexyl) phthalate (DEHP) and related
phthalate esters is their ability to elicit hepatomegaly
in rodents (1,2). This phenomenon is explained, in part,
by an increase in the cytoplasmic volume of the hepa-
tocytes due to a marked proliferation of peroxisomes
and smooth endoplasmic reticulum (2,3). The increased
volume density of these organelles is accompanied by
inductionofperoxisomal 3-oxidation andmicrosomal cy-
tochrome P452-mediated fatty acid hydroxylation (4-
6). These properties are shared with many hypolipi-
demic drugs (e.g., clofibrate, fenofibrate, ciprofibrate)
and a variety ofother chemicals such as phenoxyacetic
acid herbicides (7-14).
Several hypolipidemic drugs have elicited hepatocel-
lular carcinoma in rodents when administered for long
periods oftime at relatively high dose levels (9,15-22).
Onthisbasis, Reddy and co-workers (23) have proposed
that peroxisome proliferators represent a novel class of
chemicalcarcinogen, whichingeneral arenonmutagenic
and do not interact covalently with DNA (18,19,24-26).
It would appear that DEHP belongs to this class of
chemical, since the majority of evidence suggests it to
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lacksignificant directgenotoxicpotential(27-29). How-
ever, dietary concentrations of DEHP of up to 12,000
ppm have increased the incidence ofhepatocellular car-
cinoma in rats and mice in a two-year chronic toxicity
study (30).
It has been postulated (16) that the carcinogenic po-
tential ofperoxisome proliferators arises from "active"
02 genotoxicity, caused by imbalanced increases in
H202-generating oxidases (e.g., acyl CoA oxidase) and
H202-degrading enzymes (catalase).
Some studies have reported marked species differ-
ence in response to peroxisome proliferators. For ex-
ample, several agents, which are active in rats, have
failed to elicit peroxisome proliferation in dogs, mar-
mosets, rhesus monkeys, or guinea pigs (4,5,31-35).
However, ciprofibrate, a very potent hypolipidemic
drug, has been reported to cause hepatic peroxisome
proliferation in both rhesus and cynomolgus mohkeys
(36). Examination of human liver biopsy material; ob-
tained from patients receiving clofibrate or fenofibrate,
has demonstrated marginal or no increases in peroxi-
some numerical or volume densities (32,37-41).
In vivo, studies ofspecies differences in response to
peroxisome proliferators are frequently compromised
by variations in administered dose, target organ dose,
or differences in routes and rates ofbiotransformation.
For example, guinea pigs produce only small quantities
ofoxidized DEHPmetabolites (42), whilethemarmoset
appears to absorb only a small proportion ofan orally-
administered dose of DEHP (43).ELCOMBE AND MITCHELL
In these studies we have attempted to eliminate such
confounding factors by identifying the proximate pro-
liferator(s) derived from DEHP and examining the spe-
cies variation in response utilizing the active metabo-
lites. In addition, we also report data suggesting a
possible mechanism for DEHP elicited peroxisome pro-
liferation in rats.
Materials and Methods
Materfils
Mono(2-ethylhexyl) phthalate (MEHP), and di(2-
ethylhexyl) phthalate (DEHP) were supplied by Petro-
chemicals and Plastics Division, ICI PLC (Wilton, Mid-
dlesborough, Cleveland, UK). 1-'4C-lauric acid and 1-
"4C-palmitic acid were obtained from Amersham Inter-
national PLC (Amersham, UK).
Leibowitz L15 culture medium, fetal bovine serum,
tryptose phosphate broth and collagenase were ob-
tained from Flow Laboratories (Irvine, UK). All other
chemicals were ofthe highest available purity and were
obtained from Sigma Chemical Company (Poole, UK)
or BDH (Liverpool, UK).
Animals
Experiments were performed on male Alderley Park
rats (Wistar-derived, 180-220 g), male Alderley Park
guinea pigs (Duncan and Hartley, 400-500 g) and male
marmosets (Callithrixjacchus, 350-500 g). All animals
wereobtainedfromtheAnimalBreedingUnit, Imperial
Chemical Industries, Pharnaceuticals Division (Alder-
ley Park, Cheshire, UK). Rats and guinea pigs were
allowedfoodadlibitum, while marmosets werefed once
daily. Allanimalshadfreeaccesstowater. A12-hrlight/
dark cycle (0600-1800) was operated. Prior to isolation
of hepatocytes rats and guinea pigs were killed by in-
halationofexcessivediethylether, andmarmosets were
killed by injection of a lethal dose ofpentobarbital.
Hepatocyte Isolation and Culture
Rat and guinea pig hepatocytes were isolated by a
two-step in situ perfusion technique as described pre-
viously (44). Strict aseptic techniques were observed
throughout the procedure. Marmoset hepatocytes were
isolated in a similar manner to rat hepatocytes, except
the perfusion media were: 500 mL PBS (200 mM NaCl;
2.7 mM KCI; 1.5 mM KH2PO4; 20 mM Na2HP042H20)
followed by 500 mL ofPBS/EGTA (PBS containing 0.5
mM EGTA) and finally 200 mL (with recirculation) of
Hanks BSS (200 mM NaCl; 5.3 mM KCI; 0.4 mM
Na,HP04; 0.4 mMKH2PO4; 5.5mMglucose) containing
dispase (300 mg), collagenase (100 mg), hyaluronidase
(100 mg), deoxyribonuclease (10 mg) and CaCl22H20
(2.8 mM), pH 7.4. After about 20 min ofperfusion with
enzyme-containing solution, the liver was removed and
hepatocytes collected as described for rat liver previ-
ously.
Human liver was obtained from brain-dead renal
transplant donors after compliance with ethical and le-
gal requirements. Light and electron microscopic ex-
amination of the donor livers revealed normal mor-
phologicalandultrastructuralcharacteristics. Theouter
capsule of the liver was removed and the liver sliced
with a degreased microtome blade into slices of ap-
proximately 0.5 mm. Liver slices (10 g) were incubated
in 25 mL PBS at 37°C for 10 min. The PBS was de-
canted, and two further washes in PBS and two washes
in PBS/EGTA performed. Finally, 20 mL Hank's BSS
containing dispase (60 mg), collagenase (20 mg), hya-
luronidase (20mg), deoxyribonuclease (2mg)and CaC12
(2.8 mM) were added, and the slices incubated at 37°C
for30 min. The hepatocytes were collected byfiltration
and centrifugation as previously described.
The isolated cells were suspended in CL15 medium
i.e., Leibowitz L15 medium containing fetal bovine
serum (8.3%), tryptose phosphate broth (8.3%), peni-
cillinG(41.3 IU/mL), streptomycinsulfate (8.2 ,ug/mL),
glutamnine (241 ,ug/mL), insulin (106 M) and hydrocor-
tisone (10-' M). Vitamin C (50 mg/L) was included in
the guinea pig, marmoset, and human hepatocyte cul-
tures. The viabilities ofthe hepatocyte preparations (>
95% for animals, > 80% for human) were determined
by trypan blue dye exclusion. Falcon tissue culture
flasks (25 cm2) were seeded with 2 x 106 viable hepa-
tocytes contained in 4 mL ofCL15 medium. The flasks
were incubated at 37°C in air. At 4, 24, 48, and 72 hr
afterseeding, the spent medium and any detached cells
were aspirated and fresh medium applied. DEHP me-
tabolites dissolved in dimethylformamide (DMF) were
added to the monolayers at each 24-hr medium change.
Additions ofDMF never exceeded 10 FxL perflask, and
this concentration produced no noticeable cytotoxicity
and had no effect upon the parameters measured. Evi-
dence of cytotoxicity was manifested by blebbing,
rounding up of cells, and detachment from the flasks.
Harvesting of Cell Monolayers
At 96 hr after seeding, the monolayer cultures were
harvested. The medium was discarded and the mono-
layer washed in 2 mL of SET buffer (0.25 M sucrose/5
mM EDTA/20 mM Tris HCl, pH 7.4). The cells were
removed from the flask by scraping with a rubber po-
liceman into 1 mL ofSET bufferand were disrupted by
sonication and stored at -70°C. The enzyme activities
were stable for several weeks at this temperature.
Peroxisomal Enzyme Activity
Cyanide-insensitivefattyacid ,B-oxidation isamarker
enzyme for peroxisomes (45). Peroxisomal 1-oxidation
was measured in cell sonicates as the palmitoyl-CoA
dependent reduction of NAD+ in the presence of cya-
nide (toinhibitthemitochondrialreoxidationofNADH)
as described previously (46) with some modifications.
The assay medium contained: 60 mM Tris HCl pH 8.3,
50 ,uM FAD, 370 ,uM NAD+, 94 mM nicotinamide, 2.8
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mM dithiothreitol, 2mM KCN and 0.15 mg/mL bovine
serum albumin (fatty acid free). The enzymatic activity
was expressed as nmole NAD+ reduced/min/mg pro-
tein.
Lauric Acid Hydroxylase Activity
Cytochrome P-450-mediated lauric acid hydroxylase
activity (LAH) was assayed essentially as described be-
fore (47) with some modifications. Reaction mixtures
(37°C) contained 1 to 2 mg cellular protein, 255 nmole
(1.7 p,Ci) 1-14C-lauric acid, 1.5 ,umole NADPH in 2 mL
of 66 mM Tris HCl (pH 7.4). The reaction was termi-
nated after 10 min by the addition of500 ,L of1 M HCl
and the 14C-lauric acid and 14C-hydroxylated products
were extracted in 5 mL diethyl ether. A sample ofthe
ether extract was evaporated to dryness under N2 and
redissolved in methanol. The products were separated
by TLC on Whatman KC18F reversed-phase thin-layer
chromatography plates developed in metha-
nol:water:glacial acetic acid (80:19:5:0.5). The radioac-
tive areas were localized bfy autoradiography, scraped
from the plates, and the ' C-radioactivity determined
by liquid scintillation counting. LAH activity was ex-
pressed as nmole hydroxylated lauric acid formed/min/
mg protein.
Protein Assay
Protein was determined by the method of Lowry et
al. (48) by using bovine serum albumin standards.
Fatty Acid Oxidation by Isolated
Hepatocytes
The production of "4CO2and '4C-acid-soluble material
from 1-'4C-palmitic acid was determined in isolated rat
hepatocytes by the method of Christiansen et al. (49).
Fatty Acid Oxidation by Isolated
Mitochondria
Rat liver was homogenized (Potter-Elvehjem glass/
Teflon homogenizer, 1/20 in. clearance) in five volumes
of ice-cold 0.3 M sucrose. The homogenate was centri-
fuged at 850 gav for 10 min at 4°C. The resultant su-
pernatant was centrifuged at 10,000 gav for 20 mmn at
4°C and the resultant pellet resuspended in 0.3 M su-
crose (1 mL/g liver). The functional integrity of the
mitochondria was assessed by determination of the
P/I ratio. Using pyruvate as substrate, preparations
having a P/O ratio of less than 2.5 were discarded.
The metabolism of acyl-L-carnitines was studied in
2,4-dinitrophenol-uncoupled mitochondria in the pres-
ence ofarsenate and malonate. In this situation 02 con-
sumption. (measured polarographically using a Clarke
type 02 electrode) stoichiometrically reflects the ,-ox-
idation of the acyl-L-carnitine. A fuller explanation of
this system has been given by Sherratt and Osmundsen
(50).
FIGURE 1. Effect ofmono(2-ethylhexyl) phthalate (MEHP) on per-
oxisomal 1-oxidation of cultured rat, guinea pig, marmoset, and
human hepatocytes. Cell cultures were exposed to MEHP for 72
hr (see Methods). Values are mean -+- SD (n = 3-8). Asterisks
denote values significantly different from respective control, p <
0.05. Control values (nmole/min/mg protein) were: rat, 0.71 ±
0.18; guineapig, 0.16 ± 0.08; marmoset, 0.85 + 0.46; human, 0.11
0.04.
Statistics
Statisticalcomparisons werecarried outbyusingStu-
dent's t-test. A level of significance of p < 0.05 (two-
tailed) was chosen.
Results
Species Differences in Peroxisome
Proliferation due to MEHP and Its
Metabolites
Since DEHP is hydrolyzed in the intestine to MEHP
and is absorbed as such (51,52), the present in vitro
investigations haveutilized MEHP. The exposure ofrat
hepatocyte cultures to MEHP for 72 hr resulted in a
marked (15-fold at 0.5 mM) increase in the activity of
cyanide-insensitive palmitoyl CoA oxidation (PCO)
(Fig. 1). This was paralleled by increases in the nu-
merical and volume densities of peroxisomes (data not
shown). Similar treatment ofguinea pig and human he-
patocytes resulted in no stimulation ofPCO. Marmoset
cultures occasionally showed very small increases in
PCO, but these changes did not appear to be related to
the concentration of MEHP (Fig. 1). The guinea pig,
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FIGURE 3. Induction ofperoxisomal 3-oxidation by DEHP metabolites in cultured rat hepatocytes. Cultures were exposed to various (0-0.5
mM) concentrations of DEHP metabolites for 72 hr. Values are means ± SD (n = 4-6); asterisks denote values significantly different from
control, p < 0.05.
marmoset, and human cultures were considered to be differences in biotransformation of MEHP. Hence me-
of high viability and metabolically competent since tabolites ofMEHP were isolated from rat urine (53) and
phenobarbitone was able to induce cytochrome P-450- hepatocytes fromrat, guineapig, marmoset, andhuman
mediated ethoxycoumarin-O-deethylase in parallel cul- liver exposed to each metabolite for 72 hr. The system-
tures (Elcombe, unpublished data). atic names and structures ofthe metabolites utilized are
The use of MEHP in cultured cells, although elimi- indicated in Figure 2. Following the exposure of rat
nating differences in the hydrolysis ofDEHP to MEHP cells to the w-oxidation products ofMEHP (metabolites
and differences in the bioavailability of MEHP to the I and V) or 2-ethylhexanol, little alteration in PCO was
liver, does not allow us to eliminate possible species observed (Fig. 3). However, marked stimulationofPCO
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FIGURE 5. Induction oflauric acidhydroxylase (LAH) in rathepatocytes by DEHP metabolites. Cells wereexposed tothe various metabolites
for 72 hr. Values are means ± SD (n = 4-6).
Table 1. Effect of metabolite VI on palmitoyl CoA oxidation
(PCO) and lauric acid hydroxylation (LAH) in cultured guinea
pig, marmoset, and human hepatocytes.'
Conen Enzyme activity, % ofcontrol
Metab. VI,
Enzyme mM Guinea pig Marmoset Human
PCO 0 100±5 100±54 100±40
0.1 ND 202 ± 18 ND
0.25 166±32 ND ND
0.5 118±1 86±64 73±12
1.0 139±29 202±18 104±24
1.5 139±28 ND ND
2.0 143 ± 34 ND 69 ± 17
LAH 0 ND 100±7 100±6
0.5 ND 95±8 77±15
1.0 ND 147 ± 14 67 ± 14
2.0 ND 102 ± 8 46 ± 7
'Cells were exposed to metabolite VI for 72 hrs (see Methods).
Values are expressed as % of respective control (mean - SD, n =
3-8); ND = not determined.
Table 2. Inhibition of1-"4C-palmitic acid oxidation by
metabolite VI in isolated rat hepatocytes.
14C-Palmitate oxidation,
Concn, VI, mM rnmole oxidized/10 cells/30 mina
0 20.1 ± 1.1 (100)
0.01 19.4 ± 0.2 (96)
0.10 14.6 ± 1.1 (72)
0.50 14.4 ± 0.7 (71)
aValues are mean ± SD (n = 4) and represent the total of14CO2
released and acid-soluble 14C (acetate, hydroxybutyrate, and aceto-
acetate). Values in parentheses are % of control (in the absence of
VI).
was seen after exposure of the rat cultures to metab-
olites VI and IX (the w-1 oxidation products ofMEHP)
(Fig. 3). The proliferation ofperoxisomes by metabolite
VI was confirmed by electron microscopy (Fig. 4). Cy-
tochrome P-452-dependent lauric acid hydroxylation
(LAH) was also dramaticallyinduced in rathepatocytes
by MEHP and the w-1 oxidation product (VI), while the
w-oxidationproducts (I andV)hadmuchlesseffect(Fig.
5).
In marked contrast, the w-1 oxidation product of
MEHP (i.e., metabolite VI, active in rat cells) had little
or no effects upon PCO or LAH in marmoset, guinea
pig or human hepatocytes (Table 1).
Effects of Metabolite VI on Hepatic Fatty
Acid Oxidation
The addition ofmetabolite VI to a suspension ofiso-
lated rat hepatocytes resulted in a concentration-de-
pendent decrease in the oxidation of1-14C-palmitic acid
(Table 2), a decrease of30% being observed at 0.1 mM
metabolite VI. It should be noted thatthe experimental
design (i.e., using 1-14C-labeled fatty acid) only enabled
the effects of metabolite VI on long chain fatty acid
metabolism to be determined. The 'major proportion of
fatty acid oxidation in liver occurs in the mitochondria;
hence we have examined the effects of metabolite VI
on-the mitochondrial oxidation of 'fatty acyl-L-carni-
tines. Figure 6 clearly demonstrates a concentration-
related inhibition ofoctanoyl-L-carnitine metabolismby
metabolite VI. Conversely, palmitoyl-L-carnitine oxi-
dation'was unaffected. Further studies have demon-
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FIGURE 6. Inhibition ofacylcarnitine oxidation by metabolite VI in
isolated, uncoupled rat liver mitochondria. Palmitoyl-L-carnitine
and octanoyl-L-carnitine were used at concentrations of22 and 80
,uM, respectively. Mitochondrial protein concentration was 1-1.5
mg/mL.
strated the inhibition ofoctanoyl-L-carnitine by metab-
olite VI to be competitive (data not shown).
Discussion
The in vitro exposure of rat hepatocytes to MEHP
resulted in a marked proliferation of peroxisomes and
concomitant increases in peroxisomal P-oxidation. The
extent'ofthis stimulation was similar to orgreater than
that-observed in previous in vivo studies (4,54-56). In
contradistinction to the observations made with rat he-
patocytes, MEHP did not produce significant peroxi-
some proliferation in cultured guinea pig, marmoset or
human hepatocytes. These data compare favorably to
previously reported in vivo species differences (4,5).
Such differences between species could be explained
by adivergence in biotransformation. Forexample, the
guinea pig only produces small quantities of oxidized
DEHP metabolites (42). For this reason we have at-
tempted to exclude such metabolic factors by studying
theeffectsofDEHPmetabolitesonperoxisomalenzyme
activity. Using cultured rat hepatocytes we have iden-
tified metabolites VI and IX as peroxisome prolifera-
tors. In all probability, metabolite VI is the proximate
proliferator, since IX is metabolized to VI, which ap-
pears to be an endpoint in the oxidation ofMEHP (53).
TheadditionofmetaboliteVItoguineapig, marmoset
or human hepatocyte cultures resulted in lit'tle, ifany,
increase in peroxisomes or related enzyme activities
(PCO or LAH). This suggests that, even when the con-
founding influence of species differences in absorption
and biotransformation are eliminated, a species differ-
ence in peroxisome proliferation still exists.
These data support the suggestion ofintrinsic species
differences in the response of liver cells to peroxisome
proliferators. However, one cannob be'sure that this is
not merely a quantitative difference masquerading as a
qualitative difference inresponse. Despite this problem
of semantics, it is apparent that an impressive species
difference in sensitivity, ifnot an absolute difference in
susceptibility, exists for DEHP-elicited peroxisome
proliferation.
To resolve the question ofquantitative or qualitative
differences inresponse, studies aimed atelucidatingthe
mechanism(s) ofperoxisome proliferation are required.
It is manifest that peroxisome proliferators elicit a di-
verse number of effects upon enzymes, organelles and
cofactors involved in lipid metabolism. For example,
increased w- and p-oxidation of fatty acids, acyl CoA
hydrolases, CoA, andcarnitine areamongthemostcom-
mon observations following administration of peroxi-
some proliferators to rodents (9,12,57-61). Further-
more, similar changes are effected by high fat diets
where peroxisomal I-oxidation may be increased by up
to 8-fold (62).
In light of these observations, we suggest that in-
creased intrahepatic lipid may be an important factor
in the genesis of peroxisome proliferation. Such an ac-
cumulation of lipid may be produced in several ways;
however the present studies have shown that metabo-
lite VI, the active proliferator derived from DEHP,
inhibits fatty acid oxidation in isolated cells and selec-
tively inhibits medium chain fatty acid oxidation in iso-
lated mitochondria. This could lead to an accumulation
of medium-ch'ain fatty acids as their CoA or carnitine
esters; hence, due to depletion of essential cofactors,
leading to inhibition of all fatty acid oxidation. This
would explain the inhibition ofpalmitic acid metabolism
in isolated hepatocytes and the lack ofinhibition ofpal-
mitoyl-L-carnitine oxidation in mitochondria by metab-
olite VI. Thus, one could envisage the inhibition of ,B-
oxidation leading to accumulation oflipids and these in
turn leading to an increased synthesis oforganelles and
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enzymes involved in fatty acid oxidation, in an attempt
to maintain cellular homeostasis. Prelinminary obser-
vations (Elcombe and Mitchell, unpublished) support
such an accumulation oflipid, and attempts are in prog-
ress to isolate the lipids involved and examine their
potencies as peroxisome proliferators. Further exper-
iments are required to determine if this biochemical
lesion ofinhibition of,-oxidation is operative in species
nonresponsive to peroxisome proliferators, or whether
the initial lesion occurs but the cells do not respond to
the accumulation of lipid.
In conclusion, our data suggest that primary cultures
of hepatocytes are a sensitive and valuable model for
the study of peroxisome proliferation; allowing com-
parative potency evaluations, the identification ofprox-
imate peroxisome proliferators, and the studyofspecies
differences. Furthermore, these systems allow the ex-
clusion ofdifferences inbiotransformationwhichbedevil
many in vivo studies utilizing the parent compound or
"pro-proliferator."
From these data, we propose that an intrinsic differ-
ence in response exists between rat and human liver
cells. Hence, we suggest that, for compounds such as
DEHP, a rational human hazard assessment cannot be
made on the basis ofrat data alone. Future hazard as-
sessments will be more predictable and accurate when
a sound mechanistic basis for the phenomenon of per-
oxisome proliferation and its association with cancerare
elucidated.
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